Compare Smith & Nephew plc (SNN) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Smith & Nephew plc vs Wendys Co — how do they compare? Smith & Nephew plc trades at $27.72 (market cap $11.63B), while Wendys Co trades at $7.55 (market cap $1.45B). The key difference: Smith & Nephew plc is far larger — about 8× Wendys Co's market cap, and Wendys Co pays the higher dividend (3.68%). Which is the better fit depends on your goals.
| SNN | WEN | |
|---|---|---|
Market Cap | $11.63B | $1.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $38.53 | $9.89 |
52-Week Low | $27.80 | $6.17 |
Enterprise Value | $14.66B | $5.18B |
Dividend Yield | 2.85% | 3.68% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Wendy's stock (WEN) trades at $7.61, down 5.23% over 24 hours, reflecting recent volatility after takeover speculation faded. The stock shows a bearish technical trend with key support at $7 and resistance at $8. Fundamentally, the company has beaten EPS estimates for three consecutive quarters but faces declining net income margins, from 7.58% in 2025 to 5.72% projected for 2026. Recent news highlights CEO Bob Wright's turnaround efforts, including a new marketing chief appointment to address quality and traffic declines.
The outlook is mixed: valuation ratios like P/E of 11.54 and P/S of 0.66 appear attractive relative to peers, but execution risks persist amid competitive pressures. Analyst consensus is cautious with 64.71% hold ratings, though the $8.13 price target implies modest upside. Key risks include sustained traffic declines and high debt levels, with debt-to-asset ratio rising to 55.68% in 2025.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
